January 12, 2022 – KANSAS CITY, MO – Jurox Inc. announces it has appointed Cynthia Merritt (formerly England) to succeed Jim Van Proosdy as its US Business Manager.  Ms Merritt is a seven year veteran of Jurox, previously serving as manager of Inside Sales, Manager of National and Corporate Accounts and Director of Marketing. 

During Ms Merritt’s tenure, Jurox has experienced steady growth of its flagship Alfaxan® Multidose injectable anesthetic, with sales and customers doubling over the past three years.  “Cynthia has succeeded at every task and improved every process with which she’s been involved,” said Van Proosdy. “Her hard work and instincts contributed enormously to our recent success.”

Ms. Merritt’s internal sales roots supply her with unique insights into the veterinary customer’s anesthesia needs.  She credits in-depth knowledge of veterinarians’ surgical challenges to helping her grow the Alfaxan franchise.  “From the outset, I saw the key was education,” she said.  “Everyone, from the Jurox sales team all the way through the veterinary surgical team needed to understand how Alfaxan may improve the anesthetic experience for the patient and the veterinary staff, as well as see how strongly Jurox supports veterinary hospitals.  Education will remain the cornerstone of how I manage the Jurox business.”

Jurox manufactures Alfaxan Multidose (alfaxalone, 10 mg/mL) and Alfaxan Multidose IDX in its cGMP facility in the Hunter Valley, New South Wales, Australia.  Alfaxan is currently distributed to the U.S. veterinary market and to over 25 countries around the world. Jurox supports the highest standards of medical care by providing innovative anesthetic products and free, convenient access to continuing education via its online platform, Think Anesthesia® (www.thinkanesthesia.education). Alfaxan is a registered trademark of Jurox Pty, Ltd.